The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 28, 2010

Filed:

Aug. 17, 2005
Applicants:

Robert Clancy, Newcastle, AU;

Phillip Comans, Faulconbridge, AU;

Gerald Pang, Elizabeth Bay, AU;

Inventors:

Robert Clancy, Newcastle, AU;

Phillip Comans, Faulconbridge, AU;

Gerald Pang, Elizabeth Bay, AU;

Assignee:

Hunter Technology Limited, French Forest, AU;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 49/00 (2006.01); A61K 39/02 (2006.01); A61K 39/108 (2006.01);
U.S. Cl.
CPC ...
Abstract

There is described a method for selecting microbial isolates for use in oral killed vaccines against abnormal microbial colonization of mucosal surfaces by the microbes. The method comprises evaluating capacity of a plurality of different isolates of a microbe to activate antigen responsive cells to provide activation data for each microbial isolate, and the effectiveness of the isolates in reducing infection of a mucosal surface by the microbe to provide clearance data for each microbial isolate. An isolate, the activation data and clearance data for which correlate and is optimal for generating mucosal immunity against the microbe compared to the, or each, other of the isolates, or an isolate the activation data for which is optimal and a further isolate the clearance data for which is optimal, compared to the, or each, other of the isolates, respectively, is then selected for use in the vaccine. There is also described a method for providing an oral killed vaccine against abnormal microbial colonization of a mucosal surface, comprising evaluating the capacity of a plurality of different isolates of a microbe to induce expression of IL-10 and IL-12 in antigen responsive cells. At least one isolate is selected that induces optimal expression of IL-12 relative to IL-10 compared to the, or each, other of the isolates, respectively, for use in the vaccine.


Find Patent Forward Citations

Loading…